Keyword: Semma Therapeutics
Atara hires ex-Genentech SVP to lead R&D, Semma names former Novartis CAR-T developer as CEO, and GSK's CFO heads for the exit.
Semma Therapeutics named Bastiano Sanna, formerly of Novartis’ cell and gene therapy unit and Magenta Therapeutics, as its president and CEO.
Scientists in the U.S. and Japan devised a new tissue engineering method to tackle blood supply problems in pancreatic cell transplantation.
Researchers confirmed that the pancreas contains stem cells that can become insulin-producing cells.
The round positions Semma to start learning whether its insulin-producing cells can control blood sugar levels in Type 1 diabetics.